KEGG   DRUG: Fazpilodemab
Entry
D12490                      Drug                                   
Name
Fazpilodemab (USAN/INN)
Formula
C6418H9916N1700O2029S43
Exact mass
144643.2996
Mol weight
144732.3732
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASDFSLT TYGVHWVRQA PGKGLEWLGV IWSGGSTDYN
AAFISRLTIS KDNSKNTVYL QMNSLRAEDT AVYYCARDYG STYVDAIDYW GQGTLVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYG
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE
MTKNQVSLSC AVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLV SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
(heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFT SNYISWVRQA PGKGLEWVGE IDPYDGDTYY
ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCATGT DVMDYWGQGT LVTVSSASTK
GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS
LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF
LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYGSTYR
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN
QVSLWCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN
VFSCSVMHEA LHNHYTQKSL SLSPGK
(Light chain)
DIVLTQSPDS LAVSLGERAT INCRASESVE SYGNRYMTWY QQKPGQPPKL LIYRAANLQS
GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQSNEDPW TFGQGTKVEI KRTVAAPSVF
IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
(light chain)
DIQMTQSPSS LSASVGDRVT ITCRASQDVS TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H95, H147-H203, H223-L218, H264-H324, H370-H428, H229-h225, H232-h228, h22-h96, h219-l214, h143-h199, h260-h320, h366-h424, L23-L92, L138-L198, l23-l88, l134-l194)
  Type
Peptide
Efficacy
Hypoglycemic
  Type
Monoclonal antibody, bispecific antibody
Comment
Treatment of type 2 diabetes mellitus and non-alcoholic fatty liver disease
Target
KLB [HSA:152831] [KO:K22404]
FGFR1 (CD331) [HSA:2260] [KO:K04362]
  Pathway
hsa04714  Thermogenesis
Brite
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   FGFR family
    FGFR1 (CD331)
     D12490  Fazpilodemab (USAN/INN)
 Transporters
  Other transporters
   Auxiliary transport proteins (TC:8.A)
    KLB
     D12490  Fazpilodemab (USAN/INN)
Other DBs
CAS: 2517935-02-1
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system